• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

AstraZeneca taps Owlstone’s breath biopsy device to identify asthma, COPD biomarkers

April 9, 2018 By Sarah Faulkner

Owlstone MedicalPharmaceutical giant AstraZeneca (NYSE:AZN) inked a deal with Owlstone Medical to use the diagnostics company’s breath biopsy device to identify biomarkers for asthma and chronic obstructive pulmonary disease, the companies announced today.

Owlstone’s ReCiva breath sampler, which has CE Mark clearance in the E.U., captures volatile organic compounds in a patient’s breath. A VOC profile can be used to non-invasively diagnose disease at a very early stage and monitor treatment response, according to Owlstone.

AstraZeneca and Owlstone hope to identify disease phenotypes of COPD and asthma to better target effective treatments to the right groups of patients, the companies said.

“This agreement with AstraZeneca demonstrates our unrivalled expertise in breath biomarkers. Through our breath biopsy services we are well positioned to assist the AstraZeneca team to explore how breath biopsy can identify novel biomarkers for asthma and COPD and to optimize their application in precision medicine,” Owlstone co-founder & CEO Billy Boyle said in prepared remarks.

AstraZeneca isn’t the only pharma player that Owlstone has partnered with; in November last year, the company announced that GlaxoSmithKline (NYSE:GSK) planned to use the breath biopsy system in a phase II trial of its COPD drug, danirixin.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Diagnostics, Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development, Respiratory, Wall Street Beat Tagged With: AstraZeneca plc, GlaxoSmithKline plc, Owlstone Medical

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS